IL17RA and autoimmune disease: This drug repurposing analysis also identified the IL-6 receptor (IL6R) and IL17RA proteins as targets for the FDA-approved drugs Satralizumab and Brodalumab that are approved to treat autoimmune diseases such as neuromyelitis optica spectrum disorder (NMOSD) and severe plaque psoriasis, respectively.